Article Text

O16.4 The estimated impact and cost-effectiveness of nonavalent hpv vaccination in the united states
1. HW Chesson,
2. LE Markowitz,
3. S Hariri,
4. DU Ekwueme,
5. M Saraiya
1. Centers for Disease Control and Prevention, USA

## Abstract

Introduction The objective of this study was to assess the health impact and cost-effectiveness of human papillomavirus (HPV) vaccination strategies in the United States. Specifically, we examined the incremental costs and benefits of the 9-valent HPV vaccine (9vHPV) compared to the quadrivalent HPV vaccine (4vHPV). Like 4vHPV, 9vHPV protects against HPV types 6, 11, 16, and 18. 9vHPV also protects against 5 additional HPV types 31, 33, 45, 52, and 58.

Methods We adapted a previously published model of the impact and cost-effectiveness of 4vHPV to include the five additional HPV types in 9vHPV. The vaccine strategies we examined were (1) 4vHPV for males and females; (2) 9vHPV for females and 4vHPV for males; and (3) 9vHPV for males and females. In the base case, we assumed 9vHPV cost $13 more per dose than 4vHPV. Our model included a wide range of HPV-associated health outcomes that could potentially be averted by vaccination: cervical intraepithelial neoplasia; genital warts; juvenile-onset recurrent respiratory papillomatosis; and cervical, vaginal, vulvar, anal, oropharyngeal, and penile cancers Results Compared to no vaccination, 4vHPV for both sexes cost$5,100 to \$22,300 (in 2013 US dollars) per quality-adjusted life year (QALY) depending on assumptions regarding vaccine coverage and 4vHPV cross-protection against HPV 31, 33, 45, 52, and 58. Providing 9vHPV for females instead of 4vHPV was cost-saving in most scenarios we examined. The cost per QALY gained by providing 9vHPV to males instead of 4vHPV varied substantially depending on assumptions such as vaccine coverage and cross-protection of 4vHPV. However, the strategy of 9vHPV for both sexes (compared to the strategy of 4vHPV for both sexes) was cost-saving under most scenarios.

Conclusion A vaccination program of 9vHPV for both sexes can save money and improve health outcomes compared to a vaccination program of 4vHPV for both sexes.

Disclosure of interest statement The authors have no conflicts to declare. No pharmaceutical grants were received in the development of this study.

## Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.